| Nov 12 2015 |
FDA Fortification Policy – “Now With More Guidance!” |
Morgan, Lewis & Bockius LLP |
| Nov 11 2015 |
FDA Seeks Comments on the Meaning of "Natural" |
Keller and Heckman LLP |
| Nov 11 2015 |
Zofran Birth Defect Cases Consolidated in Boston, Massachusetts |
Stark & Stark |
| Nov 11 2015 |
FDA Requests Input on Use of the Term “Natural” for Foods |
Mintz |
| Nov 11 2015 |
Food Law Enforcement in UK: Official Statistics 2014/ 2015 and Database of Prosecutions |
Squire Patton Boggs (US) LLP |
| Nov 10 2015 |
USPTO Plans To Hike Patent Fees |
Foley & Lardner LLP |
| Nov 9 2015 |
Xarelto Court’s Utilization of Pretrial Orders and Case Management Orders to Guide and Control the Multidistrict Litigation |
Stark & Stark |
| Nov 9 2015 |
Punch to Gut: Government Denied Contempt Ruling in Bayer Probiotic Case |
Proskauer Rose LLP |
| Nov 6 2015 |
Mylan Agrees to Divest Seven Products, Including Three Pipeline Products, to Clear FTC Hurdle in Its $27 Billion Tender Offer Bid for Perrigo |
Mintz |
| Nov 5 2015 |
Where’s the Beef? Are Stricter Warning Label Requirements on the Horizon for the Meat Industry? |
Wilson Elser Moskowitz Edelman & Dicker LLP |
| Nov 5 2015 |
FTC Urges FDA to Rethink Biosimilar Naming Proposal; Other Stakeholders Agree |
Mintz |
| Nov 3 2015 |
European Pharmaceutical Giant Novartis Settles False Claims Act Whistleblower Case for $390 Million |
Tycko & Zavareei LLP |
| Nov 2 2015 |
Processed Meats Likely to Avoid California Proposition 65 Warning Labels |
Morgan, Lewis & Bockius LLP |
| Nov 2 2015 |
Food Supply Chain Issues in China (Or, China’s New Food Safety Act) (Or, Running the Gauntlet in China) |
Squire Patton Boggs (US) LLP |
| Nov 2 2015 |
Supplier to ANDA Filer Is Not Liable for Induced Infringement Until After ANDA Approval - Shire LLC v. Amneal Pharms., LLC |
McDermott Will & Emery |
| Nov 2 2015 |
Health Subcommittee to Mark Up Seven Bills; HHS Waives Fraud and Abuse Laws in Shared Savings Program; Two-Midnight Rule Revisions Finalized |
Squire Patton Boggs (US) LLP |
| Oct 30 2015 |
Estoppel in Context of Inter Partes Review Proceedings |
McDermott Will & Emery |
| Oct 29 2015 |
Marijuana in the Workplace: The Growing Conflict Between Drug and Employment Laws |
Epstein Becker & Green, P.C. |
| Oct 29 2015 |
Court Orders Re-Trial of AseraCare Falsity Phase Based on Jury Instruction Errors |
McDermott Will & Emery |
| Oct 28 2015 |
Inferior Vena Cava (IVC) Claims Are on the Rise |
Stark & Stark |
| Oct 28 2015 |
Brazil: Federal District Court in Rio de Janeiro Declares AstraZeneca’s Patent Covering Fosladex Invalid |
Michael Best & Friedrich LLP |
| Oct 27 2015 |
Recent Reports Claim Improvements in FDA’s Review of Medical Device Submissions |
Covington & Burling LLP |
| Oct 26 2015 |
Meaty Issue: Do Red and Processed Meats Cause Cancer? |
ArentFox Schiff LLP |
| Oct 26 2015 |
President Announces Efforts to Target Prescription Drug Abuse and Heroin Epidemic |
Jackson Lewis P.C. |
| Oct 23 2015 |
FDA’s Office of Planning Issues Report on Review Process for Combination Products |
Covington & Burling LLP |
| Oct 23 2015 |
Australian Patent Office Proposes “Coding Only” Sequence Ban |
Schwegman, Lundberg & Woessner, P.A. |
| Oct 22 2015 |
Medical Cannabis in Illinois: What Employers Need to Know |
Much Shelist, P.C. |
| Oct 22 2015 |
FTC Takes No Action Re: Use of “Diet” in Zero Calorie Soft Drinks; FDA Still Reviewing |
Morgan, Lewis & Bockius LLP |
| Oct 20 2015 |
D.C. Federal Court Rejects HHS Interpretation of 340B Program’s Orphan Drug Rule |
McDermott Will & Emery |
| Oct 20 2015 |
The Federal Circuit Declines To Revisit Its Decision That The Biosimilars Patent Dance Is Optional – Next Stop, Supreme Court? |
Squire Patton Boggs (US) LLP |
| Oct 20 2015 |
D.C. District Court Vacates HRSA’s Interpretative Rule on Orphan Drugs |
Epstein Becker & Green, P.C. |
| Oct 19 2015 |
No Rehearing Of Biosimilar Patent Dance Decision |
Foley & Lardner LLP |
| Oct 19 2015 |
D.C. Court Strikes Down 340B Orphan Drug Rule Again: Will This Impact the “Mega Guidance”? |
Foley & Lardner LLP |
| Oct 19 2015 |
House To Vote On ACA Repeal Provisions; HHS Projects 2016 ACA Marketplace Enrollment; HRSA’s 340B Orphan Drug Policy Struck Down Again |
Squire Patton Boggs (US) LLP |
| Oct 19 2015 |
It’s Status Quo for Now: Federal Circuit Denies Petition for Rehearing En Banc in Amgen v. Sandoz |
Michael Best & Friedrich LLP |
